PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
Ovarian cancer typically spreads throughout the peritoneal cavity, and despite standard of care treatments (surgical debulking and chemotherapy), the five-year relative survival rate remains below 50%. The use of antibody-photosensitizer conjugates (photoimmunotherapy) has emerged as a promising modality to achieve targeted photosensitizer delivery to ovarian cancer cells. In this study, we investigate epithelial growth factor (EGFR)-targeted PIT coupled with inhibition of prostaglandin E2 receptor 4 (EP4), a G-coupled-receptor that contributes to cancer progression and intracellularly transactivates EGFR. This potent triple combination significantly attenuates the metastatic behavior of ovarian cancer cells through simultaneously inducing photochemical damage and modulating protein expression.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
The alert did not successfully save. Please try again later.
Aaron Sorrin, Jocelyn Reader, Cindy Liu, Julia Cicalo, Danial Najafali, Dana Roque, Huang Chiao Huang, "Photodynamic therapy-based combination regimen with EP4 inhibitors attenuates metastatic behavior in ovarian cancer," Proc. SPIE 11628, Mechanisms and Techniques in Photodynamic Therapy and Photobiomodulation, 1162805 (5 March 2021); https://doi.org/10.1117/12.2581786